Table 3.
Meta-analysis of SOX2 expression classified by clinicopathological parameters.
| Study covariates | Studies (patients) | OR (95% CI) | I2 (%) | P h | Z | P |
|---|---|---|---|---|---|---|
| Gender (male/female) | 5 (776) | 1.628 (1.156–2.293) | 0.0 | .41 | 2.79 | <.01 |
| Age (≥60/<60) | 3 (498) | 1.086 (0.746–1.582) | 0.0 | .57 | 0.43 | .67 |
| Lauren classification (intestinal/diffuse) | 4 (619) | 1.078 (0.779–1.490) | 0.0 | .92 | 0.45 | .65 |
| LN metastasis (positive/negative) | 5 (997) | 1.105 (0.534–2.283) | 82.2 | <.01 | 0.27 | .79 |
| Distant metastasis (positive/negative) | 2 (384) | 1.792 (0.510–6.294) | 56.2 | .13 | 1.91 | .36 |
| Tumor invasion (1–2/3–4) | 6 (1065) | 0.547 (0.354–0.847) | 36.4 | .16 | 2.71 | <.01 |
| TNM stage (I–II/III–IV) | 6 (1061) | 0.800 (0.425–1.504) | 79.9 | <.01 | 0.69 | .45 |
| Vascular invasion (positive/negative) | 3 (796) | 1.515 (1.078–2.130) | 0.0 | .80 | 2.39 | .02 |
CI = confidence intervals, LN = lymph node, OR = odds ratio, P = P-value for statistical significance based on Z test, Ph = P-value for heterogeneity based on Q test.